Last reviewed · How we verify

CT-P10 — Competitive Intelligence Brief

CT-P10 (CT-P10) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor (monoclonal antibody / biosimilar). Area: Immunology / Rheumatology.

phase 3 TNF-alpha inhibitor (monoclonal antibody / biosimilar) TNF-alpha (TNF-α) Immunology / Rheumatology Biologic Live · refreshed every 30 min

Target snapshot

CT-P10 (CT-P10) — Celltrion. CT-P10 is a monoclonal antibody that binds to and inhibits TNF-alpha, reducing inflammatory signaling in autoimmune and inflammatory diseases.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CT-P10 TARGET CT-P10 Celltrion phase 3 TNF-alpha inhibitor (monoclonal antibody / biosimilar) TNF-alpha (TNF-α)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor (monoclonal antibody / biosimilar) class)

  1. Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P10 — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p10. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: